Briacell Therap (NASDAQ:BCTX) Upgraded by Wall Street Zen to Sell Rating

Posted by Scott Moore on Apr 26th, 2026

Wall Street Zen upgraded shares of Briacell Therap (NASDAQ:BCTX – Free Report) from a strong sell rating to a sell rating in a research report sent to investors on Saturday morning.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Briacell Therap in a report on Monday, April 20th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Briacell Therap has a consensus rating of “Sell”.

Check Out Our Latest Research Report on Briacell Therap

Briacell Therap Trading Up 4.0%

Shares of BCTX opened at $3.88 on Friday. Briacell Therap has a 1 year low of $3.60 and a 1 year high of $53.80. The stock has a market cap of $28.13 million, a P/E ratio of -0.17 and a beta of 1.30. The stock’s 50-day moving average price is $4.12 and its two-hundred day moving average price is $7.03.

Briacell Therap (NASDAQ:BCTX – Get Free Report) last issued its earnings results on Tuesday, March 10th. The company reported ($2.58) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Briacell Therap

An institutional investor recently bought a new position in Briacell Therap stock. Citadel Advisors LLC purchased a new position in shares of Briacell Therap (NASDAQ:BCTX – Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 11,055 shares of the company’s stock, valued at approximately $122,000. Citadel Advisors LLC owned 1.63% of Briacell Therap at the end of the most recent reporting period. 15.42% of the stock is currently owned by hedge funds and other institutional investors.

Briacell Therap Company Profile

(Get Free Report)

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.